Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; and R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d and R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.

Abstract: A polycyclic aromatic compound represented by general formula (1) described below and having a bulky substituent in a molecule is used as a material for an organic device, whereby, for example, an organic EL device excellent in quantum efficiency can be provided. In particular, concentration quenching can be suppressed even if a use concentration is comparatively high, and therefore the present art is advantageous in a device production process. In formula (1) described above, R1, R3, R4 to R7, R8 to R11 and R12 to R15 are independently hydrogen, aryl or the like, X1 is —O— or >N—R (R is aryl or the like), Z1 and Z2 are a bulky substituent such as aryl, and at least one hydrogen in the compound represented by formula (1) may be replaced by halogen or deuterium.

Abstract: Compositions and methods for optically-verified, sequence-controlled polymer synthesis are described.

Abstract: An object of the present invention is to provide a kit and a method capable of achieving high-precision measurement of a measurement target substance in a biological sample in a wide concentration range from a low concentration to a high concentration. According to the present invention, there is provided a kit for measuring a measurement target substance in a biological sample, the kit including: a labeled particle having a first binding substance capable of binding to the measurement target substance in a biological sample and having a first blocking agent; and a substrate having a second binding substance capable of binding to any one of the measurement target substance or the first binding substance and having a second blocking agent, in which the labeled particle is a luminescent labeled particle containing at least one kind of compound represented by Formula (1) and a particle, and the first blocking agent and the second blocking agent are different from each other.

Abstract: By providing a novel polycyclic aromatic compound in which a plurality of aromatic rings are linked via a boron atom, a nitrogen atom, or the like, options of a material for an organic EL element are increased. In addition, by using the novel polycyclic aromatic compound as a material for an organic electroluminescent element, an excellent organic EL element is provided.

Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d; R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.

Abstract: A catalytic process for the metal-free functionalization of sp2-carbons is described herein. The catalytic process is suitable for forming borylated alkenes, arenes and heteroarenes and comprises the use of catalysts comprising a Frustrated Lewis Pair (FLP).

Abstract: This invention relates to water-soluble mono-alkoxy and mono-alkyne BODIPY derivatives, including methods for making the same. For examples, provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: is a BODIPY ligand system; X is a halogen; L is absent or a linker; and Z is selected from the group consisting of: a group reactive with a biologically active molecule and a detectable agent.

Abstract: Using processes disclosed herein, materials and structures are created and used. For example, processes can include melting boron nitride or amorphous carbon into an undercooled state followed by quenching. Exemplary new materials disclosed herein can be ferromagnetic and/or harder than diamond. Materials disclosed herein may include dopants in concentrations exceeding thermodynamic solubility limits. A novel phase of solid carbon has structure different than diamond and graphite.

Abstract: A method for preventing or reducing low speed pre-ignition in an engine lubricated with a lubricating oil while maintaining or improving cleanliness by using as the lubricating oil a formulated oil. The formulated oil has a composition including a lubricating oil base stock as a major component, and at least one boron-containing compound and at least one overbased calcium detergent as minor components. The at least one boron-containing compound includes at least one borated dispersant, or a mixture of a boron-containing compound and a non-borated dispersant. The boron to nitrogen ratio for the at least one boron-containing compound is less than or equal to about 0.3 and the lubricating oil is essentially free of elemental magnesium. The lubricating oils of this disclosure are particularly advantageous as passenger vehicle engine oil (PVEO) products.

Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, ?-lactamase inhibitors (BLIs).

Abstract: The present invention provides a method for inhibiting structure II (sII) gas hydrate formation which comprises treating (i) a gas hydrate inhibitor and (ii) at least one additive selected from the group consisting of N-hexyl-N-methyl-pyrrolidinium tetrafluoroborate (HMP-BF4), M-hydroxyethyl-N-methyl-pyrrolidinium tetrafluoroborate (HEMP-BF4), N-ethyl-N-methyl-immidazolium tetrafluoroborate (EMIM-BF4) and N-ethyl-N-methyl-pyrrolidinium tetrafluoroborate (EMP-BF4) in water, which is in contact with a gas mixture of forming structure II gas hydrate. The additives according to the present invention can exhibit the same or greater effects of inhibiting the formation of the structure II gas hydrate through an interaction, even when the amount of a gas hydrate inhibitor is reduced.

Abstract: This invention relates to water-soluble mono-alkoxy and mono-alkyne BODIPY derivatives, including methods for making the same. For examples, provided herein are compounds of Formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein: (a) is a BODIPY ligand system; X is a halogen; L is absent or a linker; and Z is selected from the group consisting of: a group reactive with a biologically active molecule and a detectable agent.

Abstract: A printable ink for electronic applications is disclosed. The ink contains at least one non-interactive solvent, a binder, optionally one or more particulate fillers that may be conductive, semi-conductive or non-conductive, optionally a co-solvent and optionally other additives.

Abstract: The invention provides a polycyclic aromatic compound or a salt thereof having a partial structure represented by the following general formula (I): wherein X, ring A, ring B, ring C, and ring D are as defined in the specification.

Abstract: The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an animal host against the protein. The invention's VLPs are useful as, for example, vaccines.

Abstract: A lubricating oil additive composition contains a borated succinimide derivative and an amino alcohol compound. A lubricating oil composition containing the lubricating oil additive composition is excellent in high-temperature detergency and base value retention (long-drain capabilities) even though a blended content of a metal detergent is low and an ash content is small.

Abstract: An organic photoelectronic device includes a first electrode and a second electrode facing each other, and an active layer between the first electrode and the second electrode and including a first compound represented by Chemical Formula 1 or 2, and a ratio between a FWHM of a light absorption curve depending on a wavelength of the first compound in a solution state and in a thin film state satisfies the following Relationship Equation 1: FWHM2/FWHM1<2.5. In the Relationship Equation 1, FWHM1 is a FWHM of the light absorption curve depending on a wavelength in a solution state, and FWHM2 is a FWHM of the light absorption curve depending on a wavelength in a thin film state.

Abstract: Marking a petroleum product includes adding a covert dye selected from the group consisting of azadipyrromethene dyes, dipyrromethene dyes, and any combination thereof to the petroleum product and distributing the dye in the petroleum product. A petroleum product selected for analysis may be spectroscopically analyzed for the presence of an azadipyrromethene dye, a dipyrromethene dye, or a combination thereof. A concentration of at least one azadipyrromethene or dipyrromethene dye present in the portion of the petroleum product may be determined to identify the petroleum product as counterfeit, adulterated, or authentic based on the determined concentration of the azadipyrromethene or dipyrromethene dye.

Abstract: The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an animal host against the protein. The invention's VLPs are useful as, for example, vaccines.

Abstract: Method of marking a hydrocarbon liquid includes adding to the liquid a tracer compound of Formula I: wherein, each X is independently hydrogen, bromine, fluorine, a halogenated alkyl group, a linear, branched or cyclic C1-C20 alkyl group, or a phenyl group substituted with one or more halogen atoms, an alkyl group or a halogenated alkyl group; each Y is independently bromine, fluorine, a halogenated alkyl group, a branched or cyclic C1-C9 alkyl group, or a phenyl group substituted with at least one alkyl and/or a halogenated alkyl group; Z is a phenyl group substituted with one or more halogen atoms, an aliphatic or halogenated aliphatic group, a halogenated alkyl group or a linear, branched or cyclic C1-C20 alkyl group, provided that when each Y is a fluorine atom, Z is not a linear or branched C1-C20 alkyl group.

Abstract: Compounds (including polymers) for use in hybrid host materials which can be used in electroluminescent devices. The compounds comprise at least one electron-transporting moiety and at least one hole-transporting moiety which are joined by a flexible linker. Hybrid host materials comprising the compounds exhibit stability against phase separation, elevated glass transition temperature, morphological stability against crystallization, and isolation of the electron transporting moiety and hole transporting moiety ?-systems.

Abstract: The presently disclosed and claimed inventive concepts include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and ?2-antiplasmin and abnormal cell proliferation. The presently disclosed and claimed inventive concepts also include substrates of APCE and FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed and claimed inventive concepts further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma ?2-antiplasmin and to methods of treating conditions involving abnormal cell proliferation such as cancers.

Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

Abstract: Provided are methods for making and using chiral, non-racemic protected organoboronic acids, including pinene-derived iminodiacetic acid (PIDA) boronates, to direct and enable stereoselective synthesis of organic molecules. Also provided are methods for purifying PIDA boronates from solution. Also provided are methods for deprotection of boronic acids from their PIDA ligands. The purification and deprotection methods may be used in conjunction with methods for coupling or otherwise reacting boronic acids. Iterative cycles of deprotection, coupling, and purification can be performed to synthesize chiral, non-racemic compounds. The methods are suitable for use in an automated chemical synthesis process. Also provided is an automated small molecule synthesizer apparatus for performing automated stereoselective synthesis of chiral, non-racemic small molecules using iterative cycles of deprotection, coupling, and purification.

Abstract: The present invention relates to a method for preparing borinic acid derivatives and novel borinic acid derivatives. The preparing method of the present invention provides borinic acid derivatives of general formula (2): (Ar?2B(OH) ??(2) wherein Ar is the same as defined in the description and claims, selectively and in a high yield by reacting a compound of general formula (1): Ar-M, ??(1) wherein Ar and M are the same as defined in the description and claims, with tri-t-butyl borate and then hydrolyzing the reaction product.

Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.

Abstract: The invention relates to reactive ionic liquids containing organic cations with groups or substituents which are susceptible to electrochemical reduction and anions obtained from fluoroalkyl phosphates, fluoroalkyl phosphinates, fluoroalkyl phosphonates, acetates, triflates, imides, methides, borates, phosphates and/or aluminates, for use in electrochemical cells, such as lithium ion batteries and double-layer capacitors.

Abstract: Provided is an organic electroluminescent element which has improved driving voltage and improved current efficiency. An organic electroluminescent element having the above-mentioned improved characteristics is provided by using, as a material for organic electroluminescent elements, a polycyclic aromatic compound in which a nitrogen atom and another heteroatom or a metal atom (X) are adjacent to each other in a non-aromatic ring.

Abstract: The invention relates to novel fluorescent compounds derived from non-fluorinated dipyrromethene-boron, to a method for preparing same and to the use thereof for the fluorescent marking of biological molecules. The invention also relates to biological molecules marked with said fluorescent compounds, and to the use thereof in detection methods such as medical diagnosis methods. More particularly, the detection methods of the invention are particularly useful for diagnosing neurodegenerative diseases such as Alzheimer's disease.

Abstract: The inventive boronic acid analogs are potent inhibitors of Arginase I and II activity. These compounds are candidate therapeutics for treating a disease or disorder associated with an imbalance in the activity or concentration of cellular arginase I and arginase II enzymes. The invention also provides pharmaceutical compositions of the inventive compounds and methods for using the compositions for therapy.

Abstract: The present invention provides a novel ligand represented by the following formula and a novel transition metal complex having the ligand, which shows superior enantioselectivity and catalytic efficiency, particularly high catalyst activity, in various asymmetric synthesis reactions. A transition metal complex having, as a ligand, a compound represented by the formula wherein R4 is a hydrogen atom or a C1-6 alkyl group optionally having substituent(s), and R5 and R6 are each a C1-6 alkyl group optionally having substituent(s), or the formula is a group represented by the formula wherein ring B is a 3- to 8-membered ring optionally having substituent(s).

Abstract: A compound comprising a boron subphthalocyanine moiety, a plurality of solubilizing substituents positioned on peripheral cyclic groups of the boron subphthalocyanine moiety and an axial substituent positioned on the boron atom. The plurality of solubilizing substituents comprise an oxygen or sulfur containing functional group and a substituted or unsubstituted, linear, branched or cyclic, aliphatic or aromatic terminal hydrocarbyl group that is 8 or more carbon atoms in length, the hydrocarbyl group optionally containing one or more heteroatoms. The axial substituent is a cyclic group selected from the group consisting of heterocyclic amine groups, diaryl ketone groups, benzotriazole groups, benzyl alcohol groups and polycyclic aromatic hydrocarbon groups, the cyclic group being bonded to the boron atom by an oxygen containing linking moiety, the cyclic group optionally being substituted with one or more additional substituents.

Abstract: A compound comprising a boron subphthalocyanine moiety, a plurality of solubilizing substituents positioned on peripheral cyclic groups of the boron subphthalocyanine moiety and an axial substituent positioned on the boron atom of the boron subphthalocyanine moiety. The plurality of solubilizing substituents comprise an oxygen or sulfur containing functional group and a substituted or unsubstituted, linear, branched or cyclic, aliphatic or aromatic terminal hydrocarbyl group that is 8 or more carbon atoms in length, the hydrocarbyl group optionally containing one or more heteroatoms. The axial substituent is selected from the group consisting of halogen, alkyloxy, haloalkyloxy, ester, carbonyl substituted alkyl, carbonyl substituted haloalkyl, alkylaryloxy, haloalkylaryloxy, alkyl sulfonyl, haloalkyl sulfonyl, alkylaryl sulfonyl and haloalkylaryl sulfonyl.

Abstract: Carbon monoxide (CO) is a member of the gasotransmitter family that includes NO and H2S and is implicated in a variety of pathological and physiological conditions. Whereas exogenous therapeutic additions of CO to tissues and whole animals have been well studied, the real-time spatial and temporal tracking of CO at the cellular level remains an open challenge. We now report a new type of turn-on fluorescent probe for selective CO detection by exploiting palladium-mediated carbonylation reactivity. The compounds of the invention are capable of detecting CO both in aqueous buffer and in live cells with high selectivity over a range of biologically relevant reactive small molecules, providing a potentially powerful approach for interrogating its chemistry in biological systems.

Abstract: A light emitting device material containing a pyrromethene compound represented by the general formula (1). It realized a luminescent element having a high luminescent efficiency and exellent color purity. Also provided is a luminescent element employing the materials.

Abstract: The present invention relates to an ionic liquid compound that inhibits a formation of a gas hydrate. The compound of the present invention changes an equilibrium temperature and pressure of a gas hydrate in small quantity into a lower temperature and/or a higher pressure, and simultaneously retards the formation of the gas hydrate under the same environment. Thus, the compound of the present invention is used in oil and natural gas industries to effectively inhibit or delay the formation of the gas hydrate under the condition having a low temperature and a high pressure.

Abstract: The present invention relates to the improvement of organic electroluminescent devices, in particular blue-emitting devices, by using compounds of the formula (1) as dopants in the emitting layer.

Abstract: The present invention relates to compounds of Formula (I) wherein R1 and R3 are hydrogen; R2 and R4, which may be the same or different, are hydrogen, a C1-6 alkyl group optionally substituted by an aryl group which may itself be substituted, the substituent group including an alkyl group or an —OR group in which R is a C1-3 alkyl group, with one or more hydrogen atoms optionally replaced with a halogen atom; or an aryl group which may be substituted, the substituent group including an alkyl group or an —OR group in which R is a C1-3 alkyl group, with one or more hydrogen atoms optionally replaced with a halogen atom; with the proviso that R2 and R4 are not both hydrogen; the atom of R4 which is attached to C? is either a saturated carbon atom or an atom which is part of a 1 substituted aromatic ring; (AA)0-5 is an amino acid, amino acid derivative, peptide of up to 5 amino acids or a peptidomimetic thereof which optionally incorporates an N-terminal capping group, when the group is (AA)0 an N-terminal cappin

Abstract: The present invention relates to a novel indole-based compound having superior hole injection and transport capabilities, light-emitting capabilities, and the like, and an organic electroluminescent device which comprises the indole-based compound in one or more organic layers thereof so as to thereby achieve improved characteristics, such as light-emitting efficiency, driving voltage, and lifespan characteristics.

Abstract: Disclosed are hypergolic salts with borane cluster anions that ignite spontaneously upon contact with nitric acid (from 70% to 100% in water) with short ignition delay. The salts, when added as trigger additive to combustible solvent or ionic liquids, make the resulting formulation hypergolic. The salts with borane cluster anions also shorten ignition delay in hypergols, such as RP-1, and additionally allow nitric acid to be used to replace liquid oxygen as an oxidizer. In some examples, the borane salts are formed in situ in an ionic liquid.

Abstract: Embodiments of the present disclosure provide for methods of making an organoboron compound, organoboron compounds, and the like.

Abstract: Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

Abstract: A compound of formula (I) is described in which each A, which may be the same or different, is a halide selected from fluoride, chloride, bromide and iodide, or is O—Y, wherein Y is a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl moiety. R1, R2, R3, R6, R7, and R8 are each independently H, OH, NO2 or O-L-X, wherein L is a spacer group, and X is a conjugation group or a water-solubilizing group. At least one of R1, R2, R3 is OH or O-L-X and at least one of R6, R7, and R8 is OH or O-L-X. R4 and R5, which may be the same or different, are each independently H; or are a substituted or unsubstituted, saturated or unsaturated, cyclic moiety; a substituted or unsubstituted, saturated or unsaturated heterocyclic moiety; or a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl moiety. Also described are dye conjugates comprising a compound of the invention.

Abstract: The present invention is directed to a fluorescence compound represented by structural Formula (I), with specificity to neural stem cells: (I), or a pharmaceutically acceptable salt thereof. The variables for structural Formula (I) are defined herein. Also described are methods for detection of beta cells, pancreatic islets and microglia cells, comprising using a compound of structural Formula (I) or pharmaceutically acceptable salts thereof. Compounds of structural Formula (I) can also differentiate healthy pancreatic islet cells from diabetic pancreatic islet cells.

Abstract: Compounds of the formula I in which R1, R2, R3 and R4 have the meanings indicated in Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumors.

Abstract: The inventive compounds are small molecule therapeutics that are potent inhibitors of Arginase I and II activity. The invention also provides pharmaceutical compositions of the inventive compounds and methods for using the inventive compounds for treating or preventing a disease or a condition associated with arginase activity.

Abstract: The present invention is directed to a fluorescence compound represented by structural Formula (I), with specificity to neural stem cells: I or a pharmaceutically acceptable salt thereof. The variables for structural Formula (I) are defined herein. Also described are methods for detection of neural stem cells, comprising using a compound of structural Formula (I) or pharmaceutically acceptable salts thereof. Compounds of structural Formula (I) can detect and separate neural stem cells without immunostaining, providing a much shorter and more convenient method for detection of neural stem cells.

Abstract: The invention provides fluorescent sensors for the selective detection of a metal such as copper. The sensors may be considered to be derivatives of cyanine, fluorescein, rhodamine, rhodol, Tokyo green, or BODIPY. The sensors find particular use in detecting copper in cells and living animals.

Abstract: Disclosed are molecules and their synthesis, for use in blocking gated ion channels such as voltage-gated sodium channels (VGSCs) and prostate voltage sodium channels (PVSCs). These inhibitors have superior blocking efficacy, for instance in displacing the radioligand [3H]-Batrachotoxin-B ([3H]-BTX-B) that binds to site 2 of a VGSC. The molecules of the invention comprise a moiety which increases the binding affinity of molecules for the protein binding site in prostate cancer cells (PCs), and which is also fluorescent. In one embodiment the invention molecules are an inhibition system that can be used to target over-abundant or hyperactive VGSCs selectively in pain, epilepsy or prostate cancer, inhibiting the proliferation of PCs. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo.